Detalles de la búsqueda
1.
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 24(11): 1252-1265, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37844597
2.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet
; 399(10336): 1695-1707, 2022 04 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405085
3.
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Lancet Oncol
; 16(7): 787-94, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26028518
4.
A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer.
Oncologist
; 19(12): 1227-8, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25355844
5.
Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS.
J Clin Med
; 12(4)2023 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36836171
6.
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis
; 2023 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37884613
7.
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Eur Urol Oncol
; 2023 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37813745
8.
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Eur J Cancer
; 182: 66-76, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36746010
9.
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Clin Genitourin Cancer
; 21(5): 615.e1-615.e8, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37263910
10.
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Lancet Oncol
; 12(4): 369-76, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21429799
11.
TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer.
Clin Genitourin Cancer
; 19(6): 501-509, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34629300
12.
Quality of advanced ovarian cancer surgery: A French assessment of ESGO quality indicators.
Eur J Surg Oncol
; 47(2): 360-366, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32863097
13.
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
Eur J Cancer
; 159: 87-97, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34742160
14.
Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial.
Gynecol Oncol
; 116(3): 312-6, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19887304
15.
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
BJU Int
; 106(7): 974-8, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20230389
16.
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database.
Eur J Cancer
; 125: 153-163, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31787484
17.
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 37(13): 1051-1061, 2019 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30817251
18.
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
J Clin Oncol
; 37(23): 2008-2016, 2019 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31194611
19.
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.
PLoS One
; 13(9): e0204117, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30226855
20.
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Eur Urol
; 73(5): 696-703, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29074061